


Erythropoietin Drugs Market: Trends and Insights | CAGR of 5.7%

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire.com/ --

Erythropoietin/hematopoietin is a glycoprotein hormone that triggers production of red blood cells in the bone marrow through erythropoiesis. Erythropoietin drug was developed with the objective to treat anemic conditions caused from ESRD treatments and dialysis procedures. EPO drugs have gained approvals for chemotherapy-induced anemia. Advanced application of recombinant DNA technology enables production of erythropoietin for in-vitro conditions/synthetic variants, which are referred to as recombinant human erythropoietin (rHuEPO). Currently, EPO's, are largely used in anemic conditions induced from end stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART).



As per the report published by Allied Market Research, the [global Erythropoietin Drugs Market](#) was pegged at \$9.24 billion in 2020, and is estimated to reach \$14.41 billion by 2028, growing at a CAGR of 5.7% from 2021 to 2028.

Request Sample Report at: <https://www.alliedmarketresearch.com/request-sample/59>

Rise in prevalence of cancer, HIV, anemia, and kidney diseases, surge in level of awareness about the benefits of EPO therapeutics, and commercialization for erythropoietin biosimilars drive the growth of the global erythropoietin drugs market. However, longer duration of treatment, unaffordability of therapeutics, and adverse amount of side effects hinder the market growth. On the contrary, the commercialization of darbepoetin alfa biosimilar and achieving economies of scale across developed regions are expected to open lucrative opportunities for the market players in the future.

Key Takeaways:

The darbepoetin-alfa segment is estimated to register the highest CAGR of 7.0% during the forecast period.

The segment is expected to manifest the highest CAGR of 6.5% during the forecast period.

The market across Asia-Pacific is projected to register the highest CAGR of 7.8% from 2021 to 2028.

Economic Downturn Analysis:

Increased healthcare spending in developed and developing countries facilitates better access to EPO drugs.

Government funding and insurance coverage for CKD and anemia treatments directly impact market growth.

The high cost of EPO drugs can be a barrier, but the introduction of biosimilars helps reduce treatment costs and enhances market penetration.

Erythropoietin Drugs Market Segments:

By PRODUCTS:

- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others

By APPLICATIONS:

- Hematology
- Kidney Disorder
- Cancer
- Others

Geography:

- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa

Regional Analysis:

North America dominates the global erythropoietin drugs market, owing to presence of several approved and commercialized erythropoietin biosimilars. However, Asia-Pacific is characterized by presence of generic epoetin products. Asia-Pacific and LAMEA offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin drugs as compared to North America and Europe.

For Procurement Information- <https://www.alliedmarketresearch.com/purchase-enquiry/59>

Leading Market Players:

Johnson & Johnson
Amgen Inc.,
Roche, Hospira Inc.
Biocon
LG Life Sciences Ltd.
Teva Pharmaceutical Industries Ltd.
Intas Pharmaceuticals
Ranbaxy Laboratories Ltd.,
Celltrion, Inc.

Request Customization: <https://www.alliedmarketresearch.com/request-for-customization/59>

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology

includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Market Research

+ + +1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/780920150>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.